Report DMCA A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating ther
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.